ClinicalTrials.gg
Enrolling by invitationNCT07934823Updated Nov 18, 2026

How Diet Changes Affect Digestive Symptoms in Perak Athletes

An interventional study of Valens microencapsulated calcium butyrate and Low FODMAP in Gastrointestinal Symptom, Athletes and FODMAP Diet, sponsored by Universiti Tunku Abdul Rahman. Enrolling by invitation at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Universiti Tunku Abdul Rahman · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 18, 2026Primary outcomes revisedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to determine the effectiveness of a low FODMAP diet and microencapsulated oral calcium butyrate supplementation in reducing GI symptoms among athletes in Perak.

Read the detailed description

Athletes identified with at least one gastrointestinal symptoms according to the Gastrointestinal Symptom Rating Scale (GSRS) and meeting the inclusion criteria will be invited to participate in the intervention study. Following written informed consent and baseline assessment using the GSRS, participants will be randomized in a single-blind manner in a 1:1:1 into Low FODMAP diet, Microencapsulated oral calcium butyrate supplementation (3g/day) or Control group.

02

Conditions studied

  • Gastrointestinal Symptom
  • Athletes
  • FODMAP Diet
  • Butyrate
03

In context

Lead sponsor

Universiti Tunku Abdul Rahman is the lead sponsor of 37 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Athletes currently undergoing structured training at Majlis Sukan Negeri Perak (MSNPk) for at least four weeks.
  • Moderate- or vigorous-intensity athletes.
  • Able to understand the study procedures and provide written .
  • Willing to comply with all study procedures.
  • Athletes identified with at least one gastrointestinal symptom and willing to participate in the 12-week intervention period

Exclusion criteria

Exclusion Criteria:

  • Are currently consuming probiotics or have followed a gastrointestinal-specific dietary regimen (e.g., low FODMAP diet) within the previous three months.
  • Have used non-steroidal anti-inflammatory drugs (NSAIDs) or stool-altering medications (e.g., laxatives) within one month before enrolment.
  • Have a diagnosed gastrointestinal disease or disorder (e.g., inflammatory bowel disease, coeliac disease, gastrointestinal infection).
  • Have a diagnosed psychological disorder requiring active medical treatment.
  • Are unable or unwilling to comply with the study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Low FODMAP

    Participants will receive individualized dietary counselling to follow a low FODMAP diet for 12 weeks. Compliance will be monitored using 3-day food records at Weeks 4, 8, and 12.

    Behavioral: Low FODMAP

  • Active comparator
    Microencapsulated calcium butyrate

    Participants will receive microencapsulated oral calcium butyrate supplementation sachet (3g/day) providing 600 mg butyrate for 12 weeks while maintaining their usual dietary intake. Compliance will be monitored through sachet counts and participant self-report.

    Dietary Supplement: Valens microencapsulated calcium butyrate

  • Placebo comparator
    General healthy eating

    Participants will continue their habitual diet and receive individualized general healthy eating advice for 12 weeks.

    Behavioral: Habitual diet and individualized general healthy eating advice

Interventions

  • Dietary supplementValens microencapsulated calcium butyrate

    Microencapsulated oral calcium butyrate supplementation sachet (3g/day) providing 600 mg butyrate for 12 weeks while maintaining their usual dietary intake.

  • BehavioralLow FODMAP

    Individualized dietary counselling to follow a low FODMAP diet for 12 weeks.

  • BehavioralHabitual diet and individualized general healthy eating advice

    Continue their habitual diet and receive individualized general healthy eating advice for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Number of athletes with the minimum gastrointestinal symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) score at Week 12

    Number of athletes with a total Gastrointestinal Symptom Rating Scale (GSRS) score of 15 at Week 12. The 15-item scale ranges from 15 to 105, lower scores indicate fewer or less severe gastrointestinal symptoms. A score of 15 is the minimum possible total score, indicating no gastrointestinal symptoms.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in gastrointestinal symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to Weeks 4, 8, and 12

    Change in total score on the 15-item Gastrointestinal Symptom Rating Scale (GSRS) from baseline (Week 0) to Week - 4, 8, and 12 among Perak athletes. Scores range from 15 to 105, lower scores indicate fewer or less severe gastrointestinal symptoms. A score of 15 is the minimum possible total score, indicating no gastrointestinal symptoms. Change is calculated as the score at each follow-up time point minus the baseline score.

    Time frame: Baseline (Week 0) and Week - 4, 8, and 12

07

Study locations

1 site
  • Majlis Sukan Negeri Perak (MSNPk)
    Ipoh, Perak 31400, Malaysia
08

References and documents

Publications

  • Haworth, JJ, Bhatt, N, Johnson, KO, Close, GL, Kasper, AM, Wardenaar, FC, Hobson, AR, Fearn, R, Mancin, L. and Pugh, J. (2026) 'Gastrointestinal symptoms in athletes beyond endurance sports: a scoping review', Performance Nutrition, 2(1).
  • Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan;146(1):67-75.e5. doi: 10.1053/j.gastro.2013.09.046. Epub 2013 Sep 25. PubMed 24076059 ↗
  • Grace Thomas, BS, Jackie Buell. and Julie Kennel. (2022 July) A Systematic Review of the Low FODMAP Diet as a Treatment for Gastrointestinal Distress in Endurance Athletes. J Nutr Educ Behav. 54(7):S93.
  • Alruways MW. Impact of the exercise on the Gut microbiota and short-chain fatty acids (SCFAs) production. Prog. Nutr 2023;25(1).e2023010.
  • Zhao X, Chen Y, Li X, Wen W, Zhang J, Qiu J. Gastrointestinal symptoms among recreational long distance runners in China: prevalence, severity, and contributing factors. Front Nutr. 2025 Jul 23;12:1589344. doi: 10.3389/fnut.2025.1589344. eCollection 2025. PubMed 40771206 ↗
  • Wiffin M, Smith L, Antonio J, Johnstone J, Beasley L, Roberts J. Effect of a short-term low fermentable oligiosaccharide, disaccharide, monosaccharide and polyol (FODMAP) diet on exercise-related gastrointestinal symptoms. J Int Soc Sports Nutr. 2019 Jan 15;16(1):1. doi: 10.1186/s12970-019-0268-9. PubMed 30646926 ↗
  • Wardenaar FC, Schott KD, Mohr AE, Ortega-Santos CP, Connolly JE. An Exploratory Study Investigating the Prevalence of Gastrointestinal Symptoms in Collegiate Division I American Football Athletes. Int J Environ Res Public Health. 2023 Jul 27;20(15):6453. doi: 10.3390/ijerph20156453. PubMed 37568995 ↗
  • Wardenaar FC, Chan Y, Clear AM, Schott K, Mohr AE, Ortega-Santos CP, Seltzer RGN, Pugh J. The Gastrointestinal Symptom Rating Scale has a Good Test-Retest Reliability in Well-Trained Athletes With and Without Previously Self-Identified Gastrointestinal Complaints. Sports Med. 2025 Feb;55(2):513-524. doi: 10.1007/s40279-024-02122-0. Epub 2024 Oct 3. PubMed 39363029 ↗
  • van Wijck K, Lenaerts K, van Loon LJ, Peters WH, Buurman WA, Dejong CH. Exercise-induced splanchnic hypoperfusion results in gut dysfunction in healthy men. PLoS One. 2011;6(7):e22366. doi: 10.1371/journal.pone.0022366. Epub 2011 Jul 21. PubMed 21811592 ↗
  • ter Steege RW, Kolkman JJ. Review article: the pathophysiology and management of gastrointestinal symptoms during physical exercise, and the role of splanchnic blood flow. Aliment Pharmacol Ther. 2012 Mar;35(5):516-28. doi: 10.1111/j.1365-2036.2011.04980.x. Epub 2012 Jan 10. PubMed 22229513 ↗
  • Seger S, Nasharuddin NNB, Fernandez SL, Yunus SRBM, Shun NTM, Agarwal P, Burud I. Prevalence and factors associated with irritable bowel syndrome among medical students in a Malaysian private university: a cross sectional study. Pan Afr Med J. 2020 Oct 13;37:151. doi: 10.11604/pamj.2020.37.151.21716. eCollection 2020. PubMed 33425184 ↗
  • Scrivin R, Slater G, Costa RJS. Case Series: Management of Exercise-Associated Gastrointestinal Symptoms in Endurance Athletes Using a High-Carbohydrate Low-FODMAP Therapeutic Intervention. Int J Sport Nutr Exerc Metab. 2025 Mar 6;35(4):337-354. doi: 10.1123/ijsnem.2024-0133. Print 2025 Jul 1. PubMed 40049175 ↗
  • Montero-Carrasco K, Arias-Tellez MJ, Soto-Sanchez J. Use of Carbohydrate (CHO), Gluten-Free, and FODMAP-Free Diets to Prevent Gastrointestinal Symptoms in Endurance Athletes: A Systematic Review. Nutrients. 2024 Nov 11;16(22):3852. doi: 10.3390/nu16223852. PubMed 39599638 ↗
  • Mohr AE, Mach N, Pugh J, Grosicki GJ, Allen JM, Karl JP, Whisner CM. Mechanisms underlying alterations of the gut microbiota by exercise and their role in shaping ecological resilience. FEMS Microbiol Rev. 2025 Jan 14;49:fuaf037. doi: 10.1093/femsre/fuaf037. PubMed 40796291 ↗
  • Mlinaric J, Mohorko N. Nutritional strategies for minimizing gastrointestinal symptoms during endurance exercise: systematic review of the literature. J Int Soc Sports Nutr. 2025 Dec;22(1):2529910. doi: 10.1080/15502783.2025.2529910. Epub 2025 Jul 11. PubMed 40650376 ↗
  • Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017 Jan;19(1):29-41. doi: 10.1111/1462-2920.13589. Epub 2016 Dec 8. PubMed 27928878 ↗
  • Liu H, Wang J, He T, Becker S, Zhang G, Li D, Ma X. Butyrate: A Double-Edged Sword for Health? Adv Nutr. 2018 Jan 1;9(1):21-29. doi: 10.1093/advances/nmx009. PubMed 29438462 ↗
  • Lis D, Ahuja KD, Stellingwerff T, Kitic CM, Fell J. Case Study: Utilizing a Low FODMAP Diet to Combat Exercise-Induced Gastrointestinal Symptoms. Int J Sport Nutr Exerc Metab. 2016 Oct;26(5):481-487. doi: 10.1123/ijsnem.2015-0293. Epub 2016 Aug 24. PubMed 27097380 ↗
  • Lira CAB, Viana RB, Mesquista KP, Santos DAT, Campos MH, Andrade MS, Vancini RL. Frequency and intensity of gastrointestinal symptoms in exercisers individuals at rest and during physical exercise: an internet-based survey. Intest Res. 2019 Oct;17(4):537-545. doi: 10.5217/ir.2018.00162. Epub 2019 May 7. PubMed 31060114 ↗
  • Kuzmin L, Kubiak K, Lange E. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials. Nutrients. 2025 Jun 19;17(12):2045. doi: 10.3390/nu17122045. PubMed 40573159 ↗
  • Kolodziejczyk A, Staskiewicz-Bartecka W, Kardas M. The Role of FODMAPs in Sports Nutrition: A Narrative Review and Clinical Implications. Nutrients. 2026 Jan 12;18(2):239. doi: 10.3390/nu18020239. PubMed 41599852 ↗
  • Khalighi Sikaroudi M, Soltani S, Ghoreishy SM, Ebrahimi Z, Shidfar F, Dehnad A. Effects of a low FODMAP diet on the symptom management of patients with irritable bowel syndrome: a systematic umbrella review with the meta-analysis of clinical trials. Food Funct. 2024 May 20;15(10):5195-5208. doi: 10.1039/d3fo03717g. PubMed 38711328 ↗
  • Jeukendrup AE. Training the Gut for Athletes. Sports Med. 2017 Mar;47(Suppl 1):101-110. doi: 10.1007/s40279-017-0690-6. PubMed 28332114 ↗
  • Hawley JA, Forster SC, Giles EM. Exercise, the Gut Microbiome and Gastrointestinal Diseases: Therapeutic Impact and Molecular Mechanisms. Gastroenterology. 2025 Jul;169(1):48-62. doi: 10.1053/j.gastro.2025.01.224. Epub 2025 Feb 17. PubMed 39978410 ↗
  • Gasiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, Padysz M, Siedlecka M, Banasik J, Sobolewska-Wlodarczyk A, Wisniewska-Jarosinska M, Bierla JB, Otaru N, Cukrowska B, Steinert RE. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024 Dec 24;14(1):6. doi: 10.3390/jcm14010006. PubMed 39797089 ↗
  • de Oliveira EP, Burini RC, Jeukendrup A. Gastrointestinal complaints during exercise: prevalence, etiology, and nutritional recommendations. Sports Med. 2014 May;44 Suppl 1(Suppl 1):S79-85. doi: 10.1007/s40279-014-0153-2. PubMed 24791919 ↗
  • Costa RJS, Snipe RMJ, Kitic CM, Gibson PR. Systematic review: exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. Aliment Pharmacol Ther. 2017 Aug;46(3):246-265. doi: 10.1111/apt.14157. Epub 2017 Jun 7. PubMed 28589631 ↗
  • Chen Y, Zhao X, Li X, Wen W, Zhang J, Lu Z, Liang Y, Zhang C, Qiu J. Nutritional status and practices among Chinese marathon runners: data from the China marathon nutrition survey (CMNS). J Int Soc Sports Nutr. 2025 Dec;22(1):2533504. doi: 10.1080/15502783.2025.2533504. Epub 2025 Jul 15. PubMed 40662766 ↗
  • Chan YH. Randomised controlled trials (RCTs)--sample size: the magic number? Singapore Med J. 2003 Apr;44(4):172-4. No abstract available. PubMed 12952027 ↗
  • Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011 Mar 28;17(12):1519-28. doi: 10.3748/wjg.v17.i12.1519. PubMed 21472114 ↗
  • Caban M, Pikus E, Czarnecka-Chrebelska K, Oszajca K, Witusik-Perkowska M, Dudek J, Szemraj J, Brzezianska-Lasota E, Talar-Wojnarowska R. Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases-Current Clinical Approach. Dig Dis Sci. 2026 May;71(5):1626-1639. doi: 10.1007/s10620-025-09536-4. Epub 2025 Nov 14. PubMed 41238998 ↗
  • Banasiewicz T, Krokowicz L, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013 Feb;15(2):204-9. doi: 10.1111/j.1463-1318.2012.03152.x. PubMed 22738315 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared because the informed consent and ethics approvals do not authorize the release of participant-level data. The study protocol may be available from the primary investigator on reasonable request.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2026
First posted
Nov 13, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Changed Butyrate→Valens microencapsulated calcium butyrate. Added Behavioral: Low FODMAP·Behavioral: Habitual diet and individualized general healthy eating advice; removed Low FODMAP·Drug: Control
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of athletes with nothe minimum gastrointestinal symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) score at Week 12Time frame: 12 weeks
Nov 18, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange in gastrointestinal symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to Weeks 4, 8, and 12Time frame: Baseline (Week 0) and Week - 4, 8, and 12
Nov 18, 2026
Registered
First appeared on the registry
Nov 13, 2026
Show all 2 updates
  1. Nov 18, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of athletes with nothe minimum gastrointestinal symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) score at Week 12Time frame: 12 weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in gastrointestinal symptoms on the Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to Weeks 4, 8, and 12Time frame: Baseline (Week 0) and Week - 4, 8, and 12
    Interventions Changed Butyrate→Valens microencapsulated calcium butyrate. Added Behavioral: Low FODMAP·Behavioral: Habitual diet and individualized general healthy eating advice; removed Low FODMAP·Drug: Control
    + 1 other change: index terms
  2. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934823
Lead sponsor
Universiti Tunku Abdul Rahman
Responsible party
Sivanesan Rajeswaran (Lecturer in Dietetics, Universiti Tunku Abdul Rahman) — Principal investigator
First posted
Nov 13, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion